Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins.

AIDS. 1992 Nov;6(11):1249-58. Unique Identifier : AIDSLINE MED/93112294
Lamhamedi-Cherradi S; Culmann-Penciolelli B; Guy B; Kieny MP; Dreyfus F; Saimot AG; Sereni D; Sicard D; Levy JP; Gomard E; INSERM U152, ICGM, Hopital Cochin, Paris, France.


Abstract: OBJECTIVE: To study the degree of immunogenicity of each HIV-1 protein. DESIGN: In most viral systems, antiviral cytotoxic T-lymphocytes (CTL) from a given donor preferentially recognize only one or a small number of viral proteins. METHODS: Anti-HIV CTL were generated by in vitro stimulation of peripheral blood mononuclear cells from seropositive donors and tested against multiple HIV-1 proteins or groups of proteins encoded by seven genes (env, gag, pol, nef, rev, tat and vif). Using autologous target cells infected with recombinant vaccinia viruses expressing one of the HIV-1LAI proteins, we compared the cytolytic activities obtained from bulk culture with those found in limiting dilution analysis (LDA). RESULTS: Our results were noteworthy for the following reasons. (1) Each responding donor reacted simultaneously to multiple proteins; this is very unusual in other viral systems. Anti-Gag CTL were detected in most, and anti-Pol in approximately three-quarters, of the patients, together with very high amounts of the corresponding CTL precursors in LDA. CTL against Env and Nef were found in two-thirds of the patients, while Vif- and Rev-specific CTL were less frequent. Finally, Tat was seldom recognized by CTL, but its antigenicity was revealed in LDA. (2) All responding cells revealed in bulk cultures as well as in LDA were CD8+ T-cells, and their in vitro differentiation did not require the help of CD4+ T-cells. (3) Proteins from the HIV-1LAI isolate were recognized with high frequency by CTL from seropositive donors, most certainly being infected by other isolates, which suggests that relatively conserved epitopes are predominant targets of CTL. CONCLUSION: Taken together, these results are encouraging for vaccine purposes, since anti-HIV-1 CTL stimulation is thought to be a requirement for such a vaccine.
Keywords: AIDS Vaccines/IMMUNOLOGY Cytotoxicity Tests, Immunologic Cytotoxicity, Immunologic Human HIV Seropositivity/IMMUNOLOGY HIV-1/GENETICS/*IMMUNOLOGY In Vitro Retroviridae Proteins/GENETICS/*IMMUNOLOGY Support, Non-U.S. Gov't T-Lymphocyte Subsets/IMMUNOLOGY T-Lymphocytes, Cytotoxic/*IMMUNOLOGY JOURNAL ARTICLEKWDaidsvaccines/immunologycytotoxicitytests,immunologiccytotoxicity,immunologichumanhivseropositivity/immunologyhiv-1/genetics/KWDimmunologyinvitroretroviridaeproteins/genetics/KWDimmunologysupport,non-uKWDsKWDgov'tt-lymphocytesubsets/immunologyt-lymphocytes,cytotoxic/KWDimmunologyjournalarticle
930430
M9340805

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .